Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what forecast his Department has made of (a) the reduction in cases of and deaths from infection with meningococcal disease caused by groups A, C, W, and Y as a result of the introduction of the Men ACWY vaccine in 2015, (b) the number of Men ACWY vaccines which will be administered and (c) the cost of delivering that programme in each year of its operation.

The MenACWY programme was introduced in August 2015 as an emergency programme to control a national outbreak of meningococcal group W (MenW) disease.

From August 2015 to the end of August 2017 the MenACWY programme will offer a single dose of vaccine to individuals born between 1 September 1996 and 31 August 2003 inclusive. In addition, vaccines will be offered to those entering university for the first time aged up to 25 years (excluding individuals in the previously mentioned birth cohort). The number of doses given will depend on uptake, i.e. the proportion of eligible individuals who receive the vaccine.

Due to the emergency status and aims of this programme, a formal cost-effectiveness analysis was not performed, part of which would have been an estimation of the reduction in cases and deaths from invasive meningococcal disease (IMD). The MenACWY vaccine is currently replacing the MenC vaccine used in the existing adolescent and university freshers’ programmes.

The forecast cost of delivering the MenACWY programme in each year.

Note: These are the full programme costs (including cost of the vaccine) for England, inclusive of VAT.